The global pharmaceutical pricing game has a new villain and a new hero. Canada, the land of maple syrup and universal healthcare, has secured a deal for Ozempic at a fraction of the US price. Novo Nordisk, the Danish drugmaker, has agreed to supply the blockbuster diabetes drug to Canadian provinces at roughly $80 per month per patient. Meanwhile, across the border, Americans are stuck paying $900 or more for the same injection. This is not a typo. It is a market failure dressed up as capitalism.
Let us dissect this. The US pharmaceutical system, for all its free-market rhetoric, is a rigged game. It allows manufacturers to set prices with little negotiation, shielded by patent protections and a fragmented insurance system. The result? American patients subsidise the rest of the world. Canada, like the UK’s NHS, uses its single-payer clout to haggle. And it works. The Canadian deal is a direct validation of the UK’s own approach, which has long been criticised by those who believe that drug pricing should be left to the market.
But the market, as we have seen in the US, is not efficient. It is a mechanism for rent extraction. Ozempic’s price in the US has risen 18% annually, outpacing inflation by a country mile. The drug’s list price is now over $1,300 per month before insurance. After rebates and discounts, the net price is still around $900. Compare that to Canada’s $80. That is not a gap; it is a chasm.
The implications for the UK are clear. The NHS, through the National Institute for Health and Care Excellence, has historically driven hard bargains. Yet even here, Ozempic costs the NHS around £40 per month per patient, which is roughly $50 at current exchange rates. That is better than Canada but still a multiple of what some other countries pay. The real lesson is that single-payer systems wield immense power when they choose to use it. The UK’s model, often maligned as socialist interference, is actually a textbook example of monopsony power working in the public interest.
But there is a flip side. The pricing disparity is a symptom of a deeper rot: the inability of the US to control healthcare costs. With Ozempic now approved for weight loss, demand is exploding. The US could face a fiscal crisis as Medicare and Medicaid absorb these costs. Already, Novo Nordisk’s market capitalisation has surpassed the entire GDP of Denmark. The company is minting money on the backs of American patients, while Canadians and Britons pay a fair price.
Market purists will argue that price controls stifle innovation. But the evidence suggests otherwise. Novo Nordisk’s R&D spending has not dropped; it has risen. The company is not cutting back on research because Canada won’t pay US prices. It is simply taking a haircut on profits. The innovation argument is a red herring trotted out every time someone suggests that patients should not have to choose between food and medicine.
The Ozempic saga is a cautionary tale for the UK as well. If the NHS fails to maintain its negotiating teeth, we could drift towards the US model. Already, the UK’s pharmaceutical spending is rising. Generic competition for Ozempic is years away. The government must resist industry lobbying that seeks to weaken NICE’s powers. The Canadian deal proves that public negotiation works.
What about capital flight? If the US were to impose price controls, would Novo Nordisk pull investment? Unlikely. The US remains the largest market for drugs, even at lower prices. And the company’s patent exclusivity ensures a captive audience for years. The real risk is that other drugmakers follow suit. But that is a risk worth taking. The status quo is unsustainable.
Central banks should take note. The Ozempic price surge is contributing to healthcare inflation, which is a drag on real wages. The Bank of England’s inflation target does not include the cost of life-saving drugs, but it should. When a drug’s price rises faster than productivity, it erodes living standards. The UK’s low-inflation environment is partly due to NHS pricing controls. That is a feature, not a bug.
In conclusion, the Canadian Ozempic deal is a vindication for anyone who believes that healthcare is a right, not a commodity. The UK’s NHS model, with its centralised bargaining, is not just moral: it is economically efficient. The US must learn this lesson before its system bankrupts itself. And the UK must guard against complacency. The bottom line is clear: patients over profits, always.
